protective antigen


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

protective antigen

The protein made by Bacillus anthracis, which binds to cell membranes and allows the lethal components of anthrax toxin to enter and kill cells.
See also: antigen
References in periodicals archive ?
Advanced Anthrax Vaccine (dmPA7909) - a recombinant anthrax vaccine candidate, which is composed of the double-mutant protective antigen, licensed from NIAID, adsorbed to Alhydrogel([R]), combined with the immunostimulatory compound CPG 7909 (VaxImmune(TM)), licensed from Pfizer, Inc.
Recombinant anthrax toxin protective antigen (rPA) with an amino acid sequence concurring with that from the Bacillus anthracis V770-NP1-R anthrax vaccine strain was obtained from the National Institute of Craniofacial and Dental Research, National Institutes of Health, Bethesda, MD.
as a novel next-generation recombinant protective antigen (rPA)-based anthrax vaccine.
anthracis strain PA genotype Outbreak-associated I Ames I NH (2000032764) VI NH (2000032760) VI RI (2000032763) VI RI (2000032761) VI MA (2000032762) VI State A (2002017388) NA (d) Pasteur NA (d) Country B (2002007581) I Country B (2002007648) I Country B (2002007649) NA (d) Country B (2002007650) I Country B (2002007651) I (a) MLVA, multiple-locus variable-number tandem repeat analysis; pagA, protective antigen gene; PA, protective antigen; --, loci not detected; NA, not applicable.
The vaccine candidate, rPA 102, is based on a recombinant form of the protective antigen protein.
It is based on recombinant protective antigen (rPA), the principal virulence factor of the bacterial organism, B.
One of the immune correlates of protection of anthrax vaccines is likely to be the antibody response to protective antigen.
anthracis by binding to protective antigen (PA), the dominant antigen in anthrax infection, or lethal factor (LF)-proteins that work in combination to produce deadly anthrax toxins.
These proteins are known as edema factor (EF), lethal factor (LF), and protective antigen (PA).
Specifically, the mean peak concentration of antibodies to anthrax protective antigen in participants who received BioThrax plus VaxImmune was approximately 6.
C6(R) clone generation for the production of its two fully human monoclonal antibodies against the anthrax lethal toxin components Lethal Factor and Protective Antigen.